ADAR1 reports 9.9% stake in Grace Therapeutics

Grace Therapeutics, Inc. received an updated ownership report showing that ADAR1 Capital Management, related entities, and Daniel Schneeberger collectively report beneficial ownership of Grace common stock through prefunded and milestone warrants.

Rhea-AI Filing Summary

Grace Therapeutics, Inc. received an updated ownership report showing that ADAR1 Capital Management, related entities, and Daniel Schneeberger collectively report beneficial ownership of Grace common stock through prefunded and milestone warrants. ADAR1 Capital Management, LLC and Mr. Schneeberger each report beneficial ownership of 1,806,216 shares of common stock underlying these warrants, representing 9.9% of the company’s common stock based on 16,274,026 shares outstanding as of June 30, 2026. ADAR1 Capital Management GP, LLC reports 1,525,757 underlying shares, or 8.6% of the class.

The filing notes that an additional 69,331 underlying shares are excluded from the reported amounts because exchanges or exercises are subject to a 9.99% beneficial ownership limitation. Mr. Schneeberger is identified as a control person of the ADAR1 investment entities and may be deemed to indirectly beneficially own their reported positions.

Key Figures

Beneficially owned shares (ADAR1 Capital Management, LLC and Daniel Schneeberger): 1,806,216 shares Ownership percentage (ADAR1 Capital Management, LLC and Daniel Schneeberger): 9.9% Beneficially owned shares (ADAR1 Capital Management GP, LLC): 1,525,757 shares +4 more

7 metrics

Beneficially owned shares (ADAR1 Capital Management, LLC and Daniel Schneeberger) 1,806,216 shares Common stock underlying prefunded and milestone warrants as of June 30, 2026

Ownership percentage (ADAR1 Capital Management, LLC and Daniel Schneeberger) 9.9% Percentage of Grace Therapeutics common stock based on 16,274,026 shares outstanding

Beneficially owned shares (ADAR1 Capital Management GP, LLC) 1,525,757 shares Common stock underlying prefunded and milestone warrants as of June 30, 2026

Ownership percentage (ADAR1 Capital Management GP, LLC) 8.6% Percentage of Grace Therapeutics common stock based on 16,274,026 shares outstanding

Shares outstanding 16,274,026 shares Grace Therapeutics common stock outstanding as of June 30, 2026

Excluded underlying shares due to ownership cap 69,331 shares Underlying prefunded and milestone warrants subject to 9.99% beneficial ownership limitation

Beneficial ownership limitation 9.99% Cap on exchange and exercise of certain warrants for additional shares

Key Terms

prefunded and milestone warrants, beneficial ownership limitations, shared voting power, shared dispositive power, +1 more

5 terms

prefunded and milestone warrants financial

"Includes 1,806,216 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners"

beneficial ownership limitations financial

"the exchange and exercise of which are subject to 9.99% beneficial ownership limitations"

Beneficial ownership limitations are rules or contractual caps that restrict how much of a company’s stock an individual or entity can be treated as owning or controlling for legal, regulatory or corporate-governance purposes. They matter to investors because such limits affect voting power, reporting obligations, takeover risk and the ability to increase a stake — like an elevator weight limit or a lane divider that prevents any one car from taking over the whole road.

shared voting power financial

"Shared Voting Power 1,806,216.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 1,806,216.00"

control person financial

"Mr. Schneeberger is filing this as a control person in respect of shares"

A control person is an individual or entity that can significantly influence a company’s decisions and direction through ownership, voting power, or contractual rights—think of them as the captain who can steer the ship. Investors care because a control person’s choices affect corporate strategy, board appointments, and transactions that can raise or lower a stock’s value, and they often carry additional legal responsibilities and disclosure requirements to protect other shareholders.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much of Grace Therapeutics (GRCE) do the ADAR1 entities report owning?

ADAR1 Capital Management, LLC and Daniel Schneeberger each report beneficial ownership of 1,806,216 shares of Grace Therapeutics common stock underlying warrants, representing 9.9% of the outstanding common stock based on 16,274,026 shares outstanding as of June 30, 2026.

What percentage of Grace Therapeutics (GRCE) does ADAR1 Capital Management GP, LLC report?

ADAR1 Capital Management GP, LLC reports beneficial ownership of 1,525,757 shares of Grace Therapeutics common stock underlying warrants, equal to 8.6% of the company’s common stock, calculated using 16,274,026 shares outstanding as of June 30, 2026.

What is the beneficial ownership cap mentioned in the Grace Therapeutics (GRCE) Schedule 13G/A?

The filing states that 69,331 underlying shares are excluded from the reported ownership because exchanges and exercises of certain prefunded and milestone warrants are subject to a 9.99% beneficial ownership limitation, preventing ownership from exceeding that threshold.

How are ADAR1’s holdings in Grace Therapeutics (GRCE) structured?

The reported positions consist of Grace common stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC, with 1,806,216 underlying shares counted and 69,331 additional underlying shares excluded due to ownership limits.

What role does Daniel Schneeberger play in the reported Grace Therapeutics (GRCE) holdings?

Daniel Schneeberger is identified as the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC and, as a control person, may be deemed to indirectly beneficially own the 1,806,216 underlying shares reported by the ADAR1 entities.

What share count for Grace Therapeutics (GRCE) is used to calculate ownership percentages?

Ownership percentages are calculated using 16,274,026 shares of Grace Therapeutics common stock outstanding as of June 30, 2026, as reported in the company’s Form 10-Q for the quarter ended that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2026 - 05:03 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

Grace Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

00439U104

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 00439U104

1

Names of Reporting Persons

ADAR1 Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,806,216.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,806,216.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,806,216.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

IA, OO

Comment for Type of Reporting Person: Includes 1,806,216 shares of common stock, par value $0.0001 per share ("Common Stock"), underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC as of June 30, 2026. Excludes 69,331 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. Based on 16,274,026 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of June 30, 2026, reported in the Issuer's Form 10Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 13, 2026.

SCHEDULE 13G

CUSIP Number(s): 00439U104

1

Names of Reporting Persons

ADAR1 Capital Management GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,525,757.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,525,757.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,525,757.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.6 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Includes 1,525,757 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP as of June 30, 2026. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. Based on 16,274,026 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of June 30, 2026, reported in the Issuer's Form 10Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 13, 2026.

SCHEDULE 13G

CUSIP Number(s): 00439U104

1

Names of Reporting Persons

Daniel Schneeberger

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,806,216.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,806,216.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,806,216.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: Includes 1,806,216 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC as of June 30, 2026. Excludes 69,331 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. Based on 16,274,026 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of June 30, 2026, reported in the Issuer's Form 10Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 13, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Grace Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 103 Carnegie Center Suite 300 Princeton, NJ, 08540
Item 2.
(a)	Name of person filing: This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"): (i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management"); (ii) ADAR1 Capital Management GP, LLC ("ADAR1 General Partner"); and (iii) Daniel Schneeberger ("Mr. Schneeberger").
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.
(c)	Citizenship: (i) ADAR1 Capital Management is a Texas limited liability company; (ii) ADAR1 General Partner is a Texas limited liability company; and (iii) Mr. Schneeberger is a citizen of Switzerland.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 00439U104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(b)	Percent of class: The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Mr. Schneeberger is filing this Schedule 13G as a control person in respect of shares beneficially owned by ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E).
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ADAR1 Capital Management, LLC

Signature:	/s/ Daniel Schneeberger
Name/Title:	Daniel Schneeberger, Manager
Date:	08/14/2026

ADAR1 Capital Management GP, LLC

Signature:	/s/ Daniel Schneeberger
Name/Title:	Daniel Schneeberger, Manager
Date:	08/14/2026

Daniel Schneeberger

Signature:	/s/ Daniel Schneeberger
Name/Title:	Daniel Schneeberger, in his individual capacity
Date:	08/14/2026